Tirzepatide — Research Peptide Overview, Specifications, and Sourcing

At-a-Glance Specifications

CAS Number

2023788-19-2

Molecular Weight

4813.45 g/mol

Molecular Formula

C₂₂₅H₃₄₈N₄₈O₆₈

Amino Acid Sequence

39 amino acid modified GIP analog: Tyr-Aib-Glu-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Ile-Aib-Leu-Asp-Lys-Ile-Ala-Gln-Lys(C20 fatty diacid)-Ala-Phe-Val-Gln-Trp-Leu-Ile-Ala-Gly-Gly-Pro-Ser-Ser-Gly-Ala-Pro-Pro-Pro-Ser-NH2

Purity

≥99% (HPLC verified)

Physical Form

Lyophilized powder

Storage

-20°C lyophilized; 2-8°C reconstituted

Synonyms

Mounjaro (brand), Zepbound (brand), LY3298176

What Is Tirzepatide?

Tirzepatide is a first-in-class dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It is a synthetic 39-amino-acid peptide based on the native GIP sequence with key modifications that enable dual incretin receptor activation and extended pharmacokinetics. The compound was developed by Eli Lilly and Company and represents a paradigm shift in incretin-based research, moving from single-receptor to multi-receptor agonist strategies.

Structurally, tirzepatide incorporates several critical modifications to achieve its dual-agonist profile. The peptide backbone is derived from the GIP sequence, which provides high-affinity GIP receptor (GIPR) binding. Specific amino acid substitutions introduce GLP-1 receptor (GLP-1R) cross-reactivity while maintaining potent GIPR activation. An alpha-aminoisobutyric acid (Aib) substitution at position 2 confers resistance to DPP-4 enzymatic cleavage, and a C20 fatty diacid moiety attached via a linker at Lys20 enables albumin binding that extends the half-life to approximately 5 days, supporting once-weekly dosing.

Tirzepatide has demonstrated unprecedented efficacy in clinical research programs, with the SURPASS and SURMOUNT trial series establishing it as the most effective single agent studied to date for glycemic control and weight reduction in clinical trial settings. These results have generated intense research interest in dual- and multi-receptor incretin agonist strategies.

For wholesale research suppliers, tirzepatide represents a high-priority catalog compound driven by rapidly expanding demand from academic institutions, pharmaceutical R&D programs, and contract research organizations investigating the next generation of incretin-based research compounds.

Mechanism of Action

Tirzepatide’s mechanism of action is fundamentally defined by its dual incretin receptor agonism, engaging two distinct but complementary metabolic signaling pathways simultaneously.

GIP Receptor Agonism

Tirzepatide activates the GIP receptor with potency equivalent to native GIP. GIPR activation stimulates glucose-dependent insulin secretion from pancreatic beta cells and has been shown to enhance lipid metabolism in adipose tissue. Importantly, research by Samms et al. (2021) demonstrated that GIP receptor agonism contributes to weight loss through mechanisms that are distinct from and additive to GLP-1 receptor activation, including effects on adipocyte function and energy expenditure (PMID: 34293512).

GLP-1 Receptor Agonism

In addition to GIPR activation, tirzepatide engages the GLP-1 receptor, triggering the well-characterized incretin signaling cascades that include glucose-dependent insulin secretion, glucagon suppression, appetite reduction, and delayed gastric emptying. The GLP-1R component contributes to tirzepatide’s robust effects on food intake reduction and body weight loss.

Synergistic Dual-Agonist Effects

The combination of GIP and GLP-1 receptor activation produces effects that appear to exceed the sum of individual receptor activation. Coskun et al. (2018) demonstrated that tirzepatide produced greater improvements in glycemic control and body weight reduction than selective GLP-1 receptor agonism alone in preclinical models, supporting the concept of synergistic dual-agonist pharmacology (PMID: 30305981).

Metabolic Effects Beyond Incretin Signaling

Research has identified additional metabolic effects of tirzepatide including improvements in insulin sensitivity that appear disproportionate to weight loss alone, suggesting direct metabolic effects. Thomas et al. (2021) reported that tirzepatide improved insulin sensitivity in adipose tissue and skeletal muscle through mechanisms that may involve enhanced lipid storage capacity and reduced ectopic fat deposition (PMID: 34170647).

Cardiovascular and Anti-Inflammatory Mechanisms

Emerging research suggests that tirzepatide’s dual-agonist mechanism may confer cardiovascular benefits through anti-inflammatory effects, improved lipid profiles, and reductions in atherogenic markers. These cardiovascular mechanisms are under active investigation in ongoing clinical research programs.

Research Applications

Metabolic and Obesity Research

Tirzepatide has established new benchmarks in obesity research. The SURMOUNT clinical trial program demonstrated mean body weight reductions of up to 22.5% in research subjects, exceeding results observed with selective GLP-1 receptor agonists. These findings have made tirzepatide a primary reference compound in obesity research.

Diabetes Research

The SURPASS clinical program established tirzepatide’s glycemic efficacy, with HbA1c reductions and target achievement rates exceeding those of all comparator agents. Preclinical research continues to explore its effects on beta-cell function, insulin sensitivity, and glucose metabolism.

Dual-Agonist Pharmacology Research

As the first dual GIP/GLP-1 receptor agonist to reach clinical development, tirzepatide serves as a key tool compound for investigating the pharmacology of multi-receptor agonism. Researchers use tirzepatide as a reference compound in studies exploring the relative contributions of GIPR and GLP-1R activation to metabolic outcomes.

Cardiovascular Research

The SURPASS-CVOT trial is investigating tirzepatide’s cardiovascular outcomes, and preclinical research is examining its effects on atherosclerosis, cardiac function, and vascular biology.

Hepatic and Renal Research

Tirzepatide is under investigation in models of NASH/NAFLD and diabetic kidney disease, with early research suggesting benefits in both hepatic and renal endpoints.

Available Formats and Bulk Options

• Standard Research Vials: 3 mg and 5 mg lyophilized powder per vial
• High-Volume Vials: 10 mg and 15 mg per vial for higher-dose research protocols
• Bulk Lyophilized Powder: Available in 50 mg, 100 mg, 500 mg, and 1 g quantities
• Custom Formulations: Available upon request

Wholesale Pricing Summary

For detailed pricing and volume quotes, visit our wholesale pricing page or contact our B2B team.

Quality, Testing, and Certificates of Analysis

• HPLC Purity: RP-HPLC confirms ≥99% purity with full chromatographic documentation.
• Mass Spectrometry: ESI-MS/MALDI-TOF verifies molecular weight of 4813.45 g/mol and confirms C20 diacid modification.
• Amino Acid Analysis: Verifies correct 39-residue sequence including Aib substitutions.
• Endotoxin Testing: LAL assay confirms <1 EU/mg.
• Fatty Acid Conjugation: LC-MS confirms C20 fatty diacid attachment at Lys20.
• Sterility Testing: Per USP standards for in vivo presentations.

Storage and Stability

Lyophilized Form

• Long-term: -20°C or below, protected from light and moisture. Shelf life 24+ months.
• Short-term: 2-8°C for up to 4 weeks.

Reconstituted Solution

• Vehicle: Bacteriostatic water or sterile PBS (pH 7.4).
• Storage: 2-8°C for up to 14 days; aliquot and freeze at -20°C for up to 3 months.

Compliance and Intended Use

Research Use Only (RUO). Tirzepatide supplied by Wholesale Bulk Peptides is intended solely for in vitro and preclinical research by qualified investigators. This product is not intended for human or veterinary diagnostic or therapeutic use.

Tirzepatide has been approved by the FDA under brand names for specific clinical indications when manufactured under cGMP by Eli Lilly. Research-grade material from Wholesale Bulk Peptides is distinct from these products and is not intended as a substitute for FDA-approved medications.

Purchasers assume full responsibility for regulatory compliance.

Related Compounds

• Semaglutide — A selective GLP-1 receptor agonist frequently compared to tirzepatide in metabolic research.
• Retatrutide — A triple agonist (GLP-1/GIP/glucagon) representing the next step in multi-receptor agonist research.
• NAD+ — A metabolic coenzyme studied alongside incretin agonists in energy metabolism research.

References

1. Coskun T, Sloop KW, Loghin C, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab. 2018;18:3-14. PMID: 30305981
2. Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. PMID: 34170647
3. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387(4):327-340. PMID: 35658024
4. Samms RJ, Coghlan MP, Sloop KW. How may GIP enhance the therapeutic efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-421. PMID: 32396843
5. Thomas MK, Nikooienejad A, Bray R, et al. Dual GIP and GLP-1 receptor agonist tirzepatide improves beta-cell function and insulin sensitivity. J Clin Invest. 2021;131(12):e146353. PMID: 34003802

Frequently Asked Questions

What is tirzepatide?

Tirzepatide is a first-in-class dual GIP and GLP-1 receptor agonist, a synthetic 39-amino-acid peptide based on the GIP sequence with modifications enabling dual-receptor activation and an extended half-life of approximately 5 days via a C20 fatty diacid moiety.

How does tirzepatide differ from semaglutide?

Semaglutide is a selective GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors. This dual mechanism has produced superior efficacy in head-to-head clinical comparisons for glycemic control and weight reduction.

What purity is guaranteed?

All tirzepatide is supplied at 99%+ purity verified by RP-HPLC, with mass spectrometry confirmation, amino acid analysis, fatty acid conjugation verification, and endotoxin testing documented in batch-specific COAs.

How should tirzepatide be stored?

Lyophilized: -20C long-term (24+ months) or 2-8C short-term (up to 4 weeks). Reconstituted: 2-8C for up to 14 days or aliquot and freeze at -20C for up to 3 months.

What is the minimum order quantity?

Wholesale orders begin at 10 vials. Volume discounts from 12% to 45% are available at higher quantities, with custom pricing for orders exceeding 1,000 vials.

Is tirzepatide approved for human use?

Research-grade tirzepatide from Wholesale Bulk Peptides is RUO only. FDA-approved tirzepatide products (Mounjaro, Zepbound) are manufactured by Eli Lilly under pharmaceutical cGMP conditions and are distinct from research-grade material.

What research applications use tirzepatide?

Metabolic/obesity research, diabetes research, dual-agonist pharmacology studies, cardiovascular research, and hepatic/renal disease models. It serves as a benchmark compound for multi-receptor agonist strategies.

What documentation is included?

Batch-specific COA documenting HPLC purity, MS identity, amino acid analysis, endotoxin levels, fatty acid conjugation, and appearance. Safety Data Sheets available upon request.

What is the lead time?

Standard orders ship within 3-5 business days. Bulk orders may require 7-10 business days. Expedited processing available for urgent research needs.

What reconstitution vehicle is recommended?

Bacteriostatic water or sterile PBS at pH 7.4. The fatty acid modification may require gentle vortexing for complete dissolution. Reconstituted solutions should be stored at 2-8C.

Can tirzepatide be used in comparative studies?

Yes. Tirzepatide is frequently used alongside semaglutide and retatrutide in comparative efficacy studies. It serves as the benchmark dual-agonist in the expanding field of multi-receptor incretin research.

Is bulk powder available?

Yes. Tirzepatide is available as bulk lyophilized powder in quantities from 50 mg to 1 g, in addition to standard 3 mg, 5 mg, 10 mg, and 15 mg vials. Custom quantities available for institutional accounts.